

# Lucia Gozzo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5990259/lucia-gozzo-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

327

citations

8

h-index

17

g-index

29

ext. papers

505

ext. citations

4.5

avg, IF

3.64

L-index

#	Paper	IF	Citations
26	Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 832448	5.6	0
25	Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 823199	5.6	1
24	Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 748766	5.6	1
23	Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 755052	5.6	2
22	Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 641450	5.3	2
21	Regulatory, scientific, and ethical issues arising from institutional activity in one of the 90 Italian Research Ethics Committees. <i>BMC Medical Ethics</i> , <b>2021</b> , 22, 40	2.9	1
20	Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e211116-e211116	2.2	
19	Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 661882	8.4	6
18	New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	6
17	Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). <i>Annals of Hematology</i> , <b>2021</b> , 100, 481-485	3	4
16	Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 26, 100465	2.4	6
15	How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). <i>Cancer Medicine</i> , <b>2020</b> , 9, 4160-4165	4.8	11
14	Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 579886	5.6	14
13	The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 588132	5.6	8
12	The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1307	5.6	39
11	Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 621934	5.6	5
10	COVID-19 Disease and Vitamin D: A Mini-Review. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 604579	5.6	8

9	4th ESPT Conference: pharmacogenomics and personalized medicine— research progress and clinical implementation. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 1063-1069	2.6	1
8	Off-Label Use of Drugs and Adverse Drug Reactions in Pediatric Units: A Prospective, Multicenter Study. <i>Current Drug Safety</i> , <b>2018</b> , 13, 200-207	1.4	26
7	Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies. <i>Journal of Pharmacological Sciences</i> , <b>2018</b> , 138, 219-232	3.7	52
6	Safety of Antiplatelet Agents: Analysis of Real-World Data from the Italian National Pharmacovigilance Network. <i>Clinical Drug Investigation</i> , <b>2017</b> , 37, 1067-1081	3.2	6
5	Response to Letter to the Editor by Dr. Garattini. <i>Value in Health</i> , <b>2016</b> , 19, 510	3.3	
4	The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid- $\beta$ -42 oligomers in mice. <i>Pharmacological Research</i> , <b>2016</b> , 106, 10-20	10.2	21
3	Linking the Price of Cancer Drug Treatments to Their Clinical Value. <i>Clinical Drug Investigation</i> , <b>2016</b> , 36, 579-89	3.2	4
2	Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure. <i>Value in Health</i> , <b>2015</b> , 18, 131-6	3.3	47
1	The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. <i>Pharmacological Research</i> , <b>2014</b> , 87, 151-9	10.2	54